Spots Global Cancer Trial Database for dacomitinib
Every month we try and update this database with for dacomitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | NCT04511533 | Metastatic Non ... | Dacomitinib | 18 Years - | Pfizer | |
| First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | NCT05271916 | Non-Small Cell ... | Dacomitinib+Anl... Dacomitinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Phase 2 Study of Dacomitinib in NSCLC | NCT04027647 | NSCLC Stage III... NSCLC Stage III... NSCLC Stage IV Recurrent NSCLC EGFR Positive N... | Dacomitinib | 18 Years - | National Cancer Centre, Singapore | |
| Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT01918761 | Non Small Cell ... | Dacomitinib, Pe... | 18 Years - | Central European Cooperative Oncology Group | |
| ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | NCT01774721 | Non-small Cell ... | Dacomitinib (PF... Gefitinib | 18 Years - 99 Years | Pfizer | |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | NCT05834348 | Non-Small Cell ... | lorlatinib crizotinib brigatinib ceritinib alectinib atezolizumab bevacizumab paclitaxel carboplatin docetaxel erlotinib gefitinib afatinib dacomitinib osimertinib pembrolizumab nivolumab entrectinib | 18 Years - 100 Years | Pfizer | |
| Dacomitinib in Lung Cancer With Uncommon EGFR Mutations | NCT04504071 | Non-small Cell ... EGF-R Positive ... | Dacomitinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC | NCT02039336 | Colorectal Canc... | Dacomitinib PD-0325901 Docetaxel | 18 Years - | The Netherlands Cancer Institute | |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | NCT04575415 | NSCLC | Bevacizumab Erlotinib Gefitinib Icotinib Afatinib Dacomitinib Osimertinib | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | NCT04511533 | Metastatic Non ... | Dacomitinib | 18 Years - | Pfizer | |
| Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer | NCT02268747 | Skin Squamous C... | Dacomitinib | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | NCT04339829 | Dacomitinib for... | Dacomitinib | 18 Years - 80 Years | Guangdong Association of Clinical Trials | |
| A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. | NCT03755102 | EGFR Gene Mutat... Lung Cancer Lung Cancer Met... | Dacomitinib Osimertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations | NCT04811001 | NSCLC | Osimertinib Dacomitinib | 18 Years - | Fondazione Ricerca Traslazionale | |
| Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC | NCT02039336 | Colorectal Canc... | Dacomitinib PD-0325901 Docetaxel | 18 Years - | The Netherlands Cancer Institute | |
| First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | NCT05271916 | Non-Small Cell ... | Dacomitinib+Anl... Dacomitinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Dacomitinib in Lung Cancer With Uncommon EGFR Mutations | NCT04504071 | Non-small Cell ... EGF-R Positive ... | Dacomitinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. | NCT01520870 | Glioblastoma Brain Tumor, Re... | PF-299804 (Daco... | 18 Years - | Grupo Español de Investigación en Neurooncología | |
| Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO | NCT01465802 | Non Small Cell ... | Dacomitinib Dacomitinib Doxycycline Probiotic Alclometasone c... | 18 Years - | Pfizer | |
| A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | NCT01858389 | Non-small Cell ... | Dacomitinib Dacomitinib | 18 Years - | Pfizer | |
| An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | NCT04339829 | Dacomitinib for... | Dacomitinib | 18 Years - 80 Years | Guangdong Association of Clinical Trials | |
| A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer. | NCT06321510 | Lung Cancer | 18 Years - | Pfizer | ||
| A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | NCT01858389 | Non-small Cell ... | Dacomitinib Dacomitinib | 18 Years - | Pfizer | |
| A Phase II Study of Dacomitinib in Progressive Brain Metastases | NCT02047747 | Brain Cancer | Dacomitinib | 18 Years - | University of California, San Diego | |
| Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | NCT03810807 | Metastatic Non-... | Dacomitinib Osimertinib | 19 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. | NCT01520870 | Glioblastoma Brain Tumor, Re... | PF-299804 (Daco... | 18 Years - | Grupo Español de Investigación en Neurooncología | |
| Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC | NCT04768491 | EGFR Activating... NSCLC Stage IV NSCLC Stage III... NSCLC, Recurren... | Dacomitinib | 18 Years - | Peking Union Medical College | |
| Central Nervous System(CNS) Efficacy of Dacomitinib | NCT04675008 | Non Small Cell ... Brain Metastase... | Dacomitinib | 20 Years - | Samsung Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
